16 September 2026 editorial review · Trial
Sana SC451: hypoimmune stem-cell-derived islets without immunosuppression: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Corrected direct item relationships; shared class or background is insufficient.
Additional source access: Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.; Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.; The future of type 1 diabetes therapy.; Cell therapy for type 1 diabetes: Tracing historical progress and exploring emerging technologies.. Specific limit: This is an unregistered pipeline record, not a registered SC451 human trial. Accessible2025 UP421 abstract concerns a distinct donor-islet product and one patient;2026 follow-up letter metadata located but no abstract/full-text recovered. Do not treat it as SC451 human efficacy.